A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2013
At a glance
- Drugs Lonafarnib (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Adverse reactions
- 01 Aug 2011 Actual end date changed from Jan 2010 to June 2011 as reported by ClinicalTrials.gov.
- 08 Jan 2010 Actual end date (Jan 2010) and actual number of patients (37) added as reported by ClinicalTrials.gov record.
- 08 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.